OMass Therapeutics Overview
- Founded
- 2016

- Status
- Private
- Employees
- 31

- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $3.87M

- Investors
- 4
OMass Therapeutics General Information
Description
Developer of a structural mass spectrometry technology platform intended to discover novel medicines. The company's platform offers access to native mass spectrometry without having to establish sophisticated instrumentation and expertise in-house, as well as provides a way to study complex protein assemblies and their interactions with other biological molecules, enabling biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics, within a dynamic and collaborative framework.
Contact Information
- The Schrödinger Building
- Heatley Road, The Oxford Science Park
- Oxford OX4 4GE
- England, United Kingdom
OMass Therapeutics Timeline
OMass Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Early Stage VC | 21-Oct-2020 | $3.87M | 0000 | 000.00 | Completed | Generating Revenue |
3. Early Stage VC (Series A) | 13-Feb-2020 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
2. Early Stage VC (Series A) | 26-Jun-2018 | $18.6M | $21.7M | 000.00 | Completed | Generating Revenue |
1. Seed Round | 29-Mar-2016 | $3.07M | $3.07M | 00.000 | Completed | Startup |
OMass Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.00 | |
A Ordinary | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Ordinary | 1,165,513 | $0.001290 | $1.29 | $1.29 | 1x | $1.29 | 8.03% |
OMass Therapeutics Executive Team (7)
OMass Therapeutics Board Members (11)
Name | Representing | Role | Since |
---|---|---|---|
Dame Robinson | OMass Therapeutics | Co-Founder, Scientific Advisor & Board Member | 000 0000 |
Edward Hodgkin Ph.D | Syncona | Chairman | 000 0000 |
Jonathan Montagu | Self | Board Member | 000 0000 |
Lachlan MacKinnon | Oxford Sciences Innovation | Board Member | 000 0000 |
Magdalena Jonikas Ph.D | Syncona | Board Member | 000 0000 |
OMass Therapeutics Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialOMass Therapeutics Investors (4)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Syncona | Venture Capital | Minority | 000 0000 | 000000 0 | |
University of Oxford | Corporation | Minority | 000 0000 | 000000 0 | |
Oxford Sciences Innovation | Venture Capital | Minority | 000 0000 | 000000 0 | |
Oxford Spin-out Equity Management | Venture Capital | Minority | 000 0000 | 000000 0 |
OMass Therapeutics Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000000 000000 | 25-Feb-2020 | 000000000000000000 | Biotechnology | 00000000 000000 |